ALNY trades against a final fair-value range of $387.78-$974.55, with the midpoint set by the accepted valuation synthesis rather than earlier draft model outputs. Fair value range: low $388, high $975, with mid-point at $666.
Báo cáo này chưa được dịch. Hãy làm mới sau vài phút khi hàng đợi dịch xử lý xong.
§1 Tóm tắt điều hành
Composite fair value $666 with high case $975.
Implied upside of 128.0% to fair value.
Moat 9/10 · confidence 86/100 · Hyper-growth.
Trades below fair value with a meaningful cushion to the midpoint.
Fair value
$666
Margin of safety
+56.1%
Confidence
86/100
Moat
9/10
Educational analysis only — not financial advice. Always do your own due diligence.
$292.03Price
Low $387.78
Mid $665.75
High $974.55
ALNY trades against a final fair-value range of $387.78-$974.55, with the midpoint set by the accepted valuation synthesis rather than earlier draft model outputs.
First-mover advantage and foundational IP
First-mover advantage and foundational IP in RNA interference.
Established commercial infrastructure across global
Established commercial infrastructure across global rare disease markets.
Bull thesis
The market is pricing ALNY as a mature rare-disease biotech rather than an inflecting hyper-growth platform.
Based on our latest analysis, ALNY looks meaningfully undervalued. The current price is $292 versus a composite fair-value midpoint of $666 (range $388–$975), which implies roughly 128.0% upside to the midpoint.
Our composite fair-value range for ALNY is $388–$975, with a midpoint of $666. The range is triangulated across multiple valuation models (discounted earnings, forward earnings scenarios, peer multiples, and where applicable owner earnings or reverse DCF) and weighted by reliability for ALNY's archetype.
Our current rating for ALNY is Strong Buy with a confidence score of 86/100. ALNY is rated Strong Buy at $292.03 versus the reconciled fair value midpoint of $665.75, implying +127.97% upside/downside. Confidence is separately disclosed at 86/100. This is research for educational purposes, not personalized investment advice.
The top risks our latest report flags for ALNY are: Prevalent Disease Pipeline Failure; Margin Squeeze from Pricing Pressure; Genetic Medicine Disruption. The single biggest risk is Prevalent Disease Pipeline Failure: Key prevalent indication readouts, such as hypertension or obesity, fail to show superiority, restricting TAM strictly to rare diseases.
Our current rating for ALNY is Strong Buy, issued with a confidence score of 86/100 and a moat score of 9/10. The rating reflects the composite fair-value range ($388–$975) versus the current price of $292.
ALNY is classified as a hyper-growth stock. Archetype determines how every downstream parameter — discount rate, terminal growth, deceleration curve, terminal multiple, scenario probability weights, scorecard weights, and which valuation models are prioritized — is calibrated for ALNY.
